Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries

(2019) Lena Ohlsson et al.   CEPHALALGIA

Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain

(2019) Sarah L Christensen et al.   CEPHALALGIA

Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries

(2019) Eloísa Rubio-Beltrán et al.   CEPHALALGIA

Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats

(2019) Agustin Melo-Carrillo et al.   CEPHALALGIA

Identifying and managing refractory migraine: barriers and opportunities?

(2019) Linda D’Antona et al.   JOURNAL OF HEADACHE AND PAIN

Migraine and the trigeminovascular system—40 years and counting

(2019) Messoud Ashina et al.   LANCET NEUROLOGY

Targeting calcitonin gene-related peptide: a new era in migraine therapy

(2019) Andrew Charles et al.   LANCET

Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier

(2019) Rodrigo Noseda et al.   CEPHALALGIA

Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction

(2019) Anne-Sofie Grell et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Headache Pipeline: Excitement and Uncertainty

(2019) Alan M. Rapoport et al.   HEADACHE

Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal

(2018) Mi Ji Lee et al.   JOURNAL OF HEADACHE AND PAIN

Peripherally Administered CGRP Induces Spontaneous Pain in Mice

(2018) Brandon J. Rea et al.   PAIN

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

(2018) Richard B. Lipton et al.   JOURNAL OF MEDICAL ECONOMICS

Current understanding of thalamic structure and function in migraine

(2018) Samaira Younis et al.   CEPHALALGIA

Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries

(2018) Lena Ohlsson et al.   JOURNAL OF HEADACHE AND PAIN

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

(2018)   HEADACHE

Lasmiditan is an effective acute treatment for migraine

(2018) Bernice Kuca et al.   NEUROLOGY

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines

(2017) Joshua M. Cohen et al.   HEADACHE

CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study

(2017) Clara Domínguez et al.   HEADACHE

Fremanezumab - a humanized monoclonal anti-CGRP antibody — inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors

(2017) Agustin Melo-Carrillo et al.   JOURNAL OF NEUROSCIENCE

Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody

(2017) Agustin Melo-Carrillo et al.   JOURNAL OF NEUROSCIENCE

The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine

(2017) Smriti Iyengar et al.   PAIN

Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?

(2016) XiChun Zhang et al.   CEPHALALGIA

Structural Gray Matter Alterations in Chronic Migraine: Implications for a Progressive Disease?

(2016) Lars Neeb et al.   HEADACHE

Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies

(2016) Silke Miller et al.   NEUROSCIENCE

Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons

(2015) P Pozo-Rosich et al.   CEPHALALGIA

Calcitonin gene-related peptide and migraine

(2015) Nazia Karsan et al.   CURRENT OPINION IN NEUROLOGY

Migraine: Multiple Processes, Complex Pathophysiology

(2015) R. Burstein et al.   JOURNAL OF NEUROSCIENCE

OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine

(2015) Eva Cernuda-Morollón et al.   PAIN

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

(2014) Rami Burstein et al.   CEPHALALGIA

CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine

(2014) Eva Cernuda-Morollón et al.   HEADACHE

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine

(2014) John F. Rothrock et al.   HEADACHE

Calcitonin Gene-Related Peptide: Physiology and Pathophysiology

(2014) F. A. Russell et al.   PHYSIOLOGICAL REVIEWS

Differentiation of Nerve Fibers Storing CGRP and CGRP Receptors in the Peripheral Trigeminovascular System

(2013) Sajedeh Eftekhari et al.   JOURNAL OF PAIN

Two Mechanisms Involved in Trigeminal CGRP Release: Implications for Migraine Treatment

(2012) Paul L. Durham et al.   HEADACHE

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation

(2011) Ann C. Raddant et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Low-Dose Topiramate Plus Sodium Divalproate for Positive Responders Intolerant to Full-Dose Monotherapy

(2011) Abouch Valenty Krymchantowski et al.   HEADACHE

Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders

(2011) Abouch Valenty Krymchantowski et al.   JOURNAL OF HEADACHE AND PAIN

Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1β pro-inflammatory effects

(2011) Alice De Corato et al.   JOURNAL OF NEUROIMMUNOLOGY

Activation of central trigeminovascular neurons by cortical spreading depression

(2010) XiChun Zhang et al.   ANNALS OF NEUROLOGY

CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine

(2010) JF Tvedskov et al.   CEPHALALGIA

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

(2010) Jakob Møller Hansen et al.   CEPHALALGIA

Activation of Meningeal Nociceptors by Cortical Spreading Depression: Implications for Migraine with Aura

(2010) X. Zhang et al.   JOURNAL OF NEUROSCIENCE

Permeability of the Paranodal Junction of Myelinated Nerve Fibers

(2010) A. Mierzwa et al.   JOURNAL OF NEUROSCIENCE

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion

(2010) S. Eftekhari et al.   NEUROSCIENCE

Barriers to Satisfactory Migraine Outcomes. What Have We Learned, Where Do We Stand?

(2009) Marcelo Bigal et al.   HEADACHE

Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential

(2009) J. Meng et al.   JOURNAL OF NEUROSCIENCE

Preventive Migraine Treatment

(2009) Stephen D. Silberstein   NEUROLOGIC CLINICS

Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction

(2009) Y. Kitamura et al.   NEUROSCIENCE

Migraine: where and how does the pain originate?

(2009) Karl Messlinger   EXPERIMENTAL BRAIN RESEARCH

Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation

(2008) Alvaro Lucioni et al.   BJU INTERNATIONAL

Treatment of migraine with prophylactic drugs

(2008) Stefan Evers   EXPERT OPINION ON PHARMACOTHERAPY

Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society

(2008) Elliott A. Schulman et al.   HEADACHE

Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution

(2008) Jochen K. Lennerz et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET

Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin

(2008) Parisa Gazerani et al.   PAIN